Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results

– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events –


– Reduction in incidences of microbiome pathogen... | May 9, 2023

Related Keywords

United States , American , Matthew Henn , International Blood , Nasdaq , American Health Drug , Marrow Transplant Research , Exchange Commission , Health Science , Seres Therapeutics Inc , Seres Therapeutics , Chief Medical Officer , Study Design , Chief Scientific Officer , Hematologic Malignancies , Memorial Sloan Kettering Cancer Center , Infection Protection , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Allogeneic Hematopoietic Cell , Intestinal Domination , Clinical Infectious , Hematopoietic Stem Cell Transplantation , American Health , Nc Stock Exchange , News , Information , Press Release , Tolerability , Profile , Bserved , Supports , Ontinued , Development , N , Cohort , Ith , O , Treatment , Aattributed , Serious , Madverse , Events , Reduction , Incidences , F , Icrobiome Mcrb Us81750r1023 ,